MCID: RSP002
MIFTS: 51

Respiratory Syncytial Virus Infectious Disease

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Respiratory Syncytial Virus Infectious Disease

MalaCards integrated aliases for Respiratory Syncytial Virus Infectious Disease:

Name: Respiratory Syncytial Virus Infectious Disease 12
Respiratory Syncytial Virus Infections 44 70
Respiratory Syncytial Virus Infection 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1273
MeSH 44 D018357
NCIt 50 C3354
SNOMED-CT 67 186750007
UMLS 70 C0035235

Summaries for Respiratory Syncytial Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in upper respiratory tract or located in lower respiratory tract, has material basis in Human respiratory syncytial virus, which is transmitted by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted by contaminated fomites. The infection has symptom runny nose, has symptom fever, has symptom cough, has symptom wheezing, and has symptom respiratory distress.

MalaCards based summary : Respiratory Syncytial Virus Infectious Disease, also known as respiratory syncytial virus infections, is related to hypereosinophilic syndrome and ige responsiveness, atopic, and has symptoms including fever, cough and respiratory distress. An important gene associated with Respiratory Syncytial Virus Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Immunoglobulins, Intravenous and Palivizumab have been mentioned in the context of this disorder. Affiliated tissues include upper respiratory tract, lower respiratory tract and bone marrow.

Related Diseases for Respiratory Syncytial Virus Infectious Disease

Diseases related to Respiratory Syncytial Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 hypereosinophilic syndrome 31.2 IL5 IL13 CCL5
2 ige responsiveness, atopic 31.1 IL5 IL13
3 bronchiolitis 31.0 IL5 IL13 CCL5 CCL3
4 eosinophilic pneumonia 30.9 IL5 IL13 CCL5
5 bronchitis 30.7 IL5 IL13 CCL5
6 viral pneumonia 30.7 IFNB1 CCL5
7 pulmonary eosinophilia 30.6 IL5 IL13 CCL5 CCL3
8 respiratory allergy 30.5 IL5 IL13
9 rhinitis 30.5 IL5 IL13 CCL5
10 allergic disease 30.5 IL5 IL13 CCL5
11 cytokine deficiency 30.5 IL5 IL13
12 dermatitis, atopic 30.4 IL5 IL13 CCL5
13 influenza 30.3 NEU1 IFNB1 CCL5
14 pollen allergy 30.3 IL5 IL13
15 allergic rhinitis 30.3 IL5 IL13 CCL5
16 allergic asthma 30.3 IL5 IL13 CCL5 CCL3
17 parainfluenza virus type 3 30.2 NEU1 IFNB1
18 asthma 30.2 IRF1 IL5 IL13 CCL5 CCL3
19 aspergillosis 30.2 IL5 CCL5 CCL3
20 common cold 30.1 IL5 IL13 CCL5
21 bronchial disease 30.1 IL5 IL13 CCL5
22 nasopharyngitis 30.1 IL5 IFNB1
23 lung disease 30.0 SFTPB IL5 IL13 CCL5 CCL3
24 interstitial lung disease 29.9 SFTPB IL5 IL13 CCL5
25 bacterial pneumonia 29.9 SFTPB NEU1 CCL3
26 celiac disease 1 29.9 IRF1 IL5 IL13
27 respiratory failure 29.8 SFTPB NEU1 IL5 IL13 CCL5
28 proteasome-associated autoinflammatory syndrome 1 29.8 IL5 IL13 CCL5 CCL3
29 encephalitis 29.8 IFNB1 CCL5 CCL3
30 newcastle disease 29.7 NEU1 IFNB1
31 diarrhea 29.7 IL5 IL13 IFNB1
32 pulmonary disease, chronic obstructive 29.4 SFTPB IL5 IL13 CCL5 CCL3
33 pulmonary fibrosis, idiopathic 29.4 SFTPB IL5 IL13 CCL5 CCL3
34 viral infectious disease 29.0 NEU1 IRF1 IL13 IFNB1 CCL5 CCL3
35 pneumonia 29.0 SFTPB NEU1 IL5 IL13 CCL5 CCL3
36 immune deficiency disease 28.9 IRF1 IL13 IFNB1 CCL5 CCL3
37 systemic lupus erythematosus 28.9 IRF1 IL5 IL13 IFNB1 CCL5
38 bronchopulmonary dysplasia 10.6
39 hypotrichosis and recurrent skin vesicles 10.6
40 down syndrome 10.6
41 heart disease 10.6
42 fibrosis of extraocular muscles, congenital, 1 10.5
43 bronchopneumonia 10.5
44 otitis media 10.4
45 severe combined immunodeficiency 10.4
46 47,xyy 10.4
47 combined immunodeficiency 10.4
48 neutropenia 10.4
49 bacterial infectious disease 10.3
50 leukemia, acute lymphoblastic 10.3

Graphical network of the top 20 diseases related to Respiratory Syncytial Virus Infectious Disease:



Diseases related to Respiratory Syncytial Virus Infectious Disease

Symptoms & Phenotypes for Respiratory Syncytial Virus Infectious Disease

Symptoms:

12
  • fever
  • cough
  • respiratory distress
  • wheezing
  • runny nose

UMLS symptoms related to Respiratory Syncytial Virus Infectious Disease:


fever; pruritus; snoring; coughing

Drugs & Therapeutics for Respiratory Syncytial Virus Infectious Disease

Drugs for Respiratory Syncytial Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins, Intravenous Phase 4
2
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
3
Ribavirin Approved Phase 3 36791-04-5 37542
4 Calamus Phase 3
5 Antibodies, Monoclonal Phase 3
6 Pharmaceutical Solutions Phase 3
7 Anti-Infective Agents Phase 3
8 Antiviral Agents Phase 3
9 Antimetabolites Phase 3
10
tannic acid Approved Phase 2 1401-55-4
11
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
12
Coal tar Approved Phase 2 8007-45-2
13
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
14
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
15
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
16 Immunologic Factors Phase 1, Phase 2
17 Vaccines Phase 2
18 Iron-Dextran Complex Phase 2
19 PC786 Phase 2
20
Histidine Investigational, Nutraceutical Phase 2 71-00-1 6274
21
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
22
Rifampicin Approved Phase 1 13292-46-1 5381226 5458213
23
Verapamil Approved Phase 1 52-53-9 2520
24
Itraconazole Approved, Investigational Phase 1 84625-61-6 55283
25
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
26
BCG vaccine Approved, Investigational Phase 1
27
Quinidine Approved, Investigational Phase 1 56-54-2 441074
28
Prednisone Approved, Vet_approved Phase 1 53-03-2 5865
29
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
30
Tacrolimus Approved, Investigational Phase 1 104987-11-3 6473866 445643 439492
31
Dabigatran Investigational Phase 1 211914-51-1
32 Cytochrome P-450 CYP3A Inhibitors Phase 1
33 Antibiotics, Antitubercular Phase 1
34 polysaccharide-K Phase 1
35 Anti-Arrhythmia Agents Phase 1
36 Vasodilator Agents Phase 1
37 Cytochrome P-450 Enzyme Inhibitors Phase 1
38
Hydroxyitraconazole Phase 1 108222
39 Hormone Antagonists Phase 1
40 Hormones Phase 1
41 Anti-Bacterial Agents Phase 1
42 Antitubercular Agents Phase 1
43 calcium channel blockers Phase 1
44 Antifungal Agents Phase 1
45 Adrenergic Agents Phase 1
46 Adrenergic alpha-Antagonists Phase 1
47 Adrenergic Antagonists Phase 1
48 Sodium Channel Blockers Phase 1
49 Muscarinic Antagonists Phase 1
50 Quinidine gluconate Phase 1

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants Completed NCT02325791 Phase 3 Suptavumab 30 mg/kg;Placebo Matched to Suptavumab;Suptavumab 30 mg/kg- 1 Dose;Suptavumab 30 mg/kg - 2 Doses
3 A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children Completed NCT00129766 Phase 3
4 A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants Completed NCT02624947 Phase 3
5 Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed NCT01466062 Phase 3 Palivizumab
6 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
7 Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study Completed NCT03171142 Phase 3 Heliox;Air
8 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) Recruiting NCT03979313 Phase 3 MEDI8897;Placebo
9 A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY) Recruiting NCT03959488 Phase 2, Phase 3 MEDI8897;Palivizumab
10 A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above Recruiting NCT04732871 Phase 3
11 A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age Recruiting NCT04605159 Phase 3 Placebo
12 A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants Recruiting NCT04767373 Phase 2, Phase 3 Placebo
13 A Randomized, Double-blind, Placebo-controlled, 2-part Study of Orally Administered AK0529 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Multiple Doses in Hospitalized Infants With Respiratory Syncytial Virus Infection Not yet recruiting NCT04231968 Phase 3 AK0529;Matching placebo of AK0529
14 A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient Terminated NCT00031473 Phase 3 Virazole (Ribavirin) Inhalation Solution
15 A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects Completed NCT02387606 Phase 2 Placebo;JNJ-53718678
16 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model Completed NCT02094365 Phase 2 ALS-008176;vehicle
17 A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection Completed NCT02654171 Phase 2 AK0529;Placebo
18 A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Completed NCT03332459 Phase 2 Lumicitabine;Placebo
19 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model Completed NCT03258502 Phase 2 RV521;Placebo
20 A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease Completed NCT00192478 Phase 1, Phase 2
21 Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years Completed NCT03814590 Phase 1, Phase 2 Placebo (Saline solution)
22 Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain) Completed NCT01756482 Phase 2 GS-5806;Placebo
23 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life Completed NCT02247726 Phase 2 Saline Placebo (0.5mL injection);RSV F vaccine (0.5mL injection)
24 A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT01065935 Phase 2 ALN-RSV01;Normal Saline
25 A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation Completed NCT00232635 Phase 2 A-60444
26 A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus Completed NCT00496821 Phase 2 ALN-RSV01
27 An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women Completed NCT02360475 Phase 2
28 A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season Completed NCT00316264 Phase 2
29 An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed NCT02753413 Phase 2
30 An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women Completed NCT02956837 Phase 2 Placebo (Formulation buffer S9b)
31 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants Completed NCT02927873 Phase 2 Placebo LD;Placebo MD;Placebo HD
32 A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT00658086 Phase 2 ALN-RSV01;normal saline
33 A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine Completed NCT02873286 Phase 2
34 A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus Completed NCT03379675 Phase 2 JNJ-53718678 500 mg;JNJ-53718678 80 mg;Placebo
35 A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness Completed NCT02673476 Phase 2 ALS-008176;Placebo
36 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age Completed NCT01960686 Phase 2
37 A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants Completed NCT02878330 Phase 2 MEDI8897;Placebo
38 A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model Completed NCT03382431 Phase 1, Phase 2 PC786;Placebo/vehicle
39 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Completed NCT02254421 Phase 2 Presatovir;Placebo
40 A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care. Completed NCT02309320 Phase 1, Phase 2
41 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed NCT02135614 Phase 2 Presatovir;Presatovir placebo
42 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model Completed NCT02718937 Phase 2 BTA-C585 oral capsule;Matching placebo capsules
43 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model. Completed NCT03691623 Phase 2 EDP-938 Dose 1;EDP-938 Dose 2;Placebo;EDP-938 Dose 3;EDP-938 Dose 4;Placebo
44 An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults Completed NCT03334695 Phase 2 Placebo
45 An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant Completed NCT01502072 Phase 2 Ribavirin;Ribavirin
46 A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection Recruiting NCT03656510 Phase 2 JNJ-53718678;Placebo
47 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Recruiting NCT04633187 Phase 2 EDP-938;Placebo
48 A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection Recruiting NCT03699202 Phase 2 AK0529;Placebo
49 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Recruiting NCT04056611 Phase 2 JNJ-53718678 250 mg;Placebo;JNJ-53718678 125 mg
50 A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults Recruiting NCT04785612 Phase 2

Search NIH Clinical Center for Respiratory Syncytial Virus Infectious Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Immunoglobulins, Intravenous
palivizumab
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
Ribavirin

Cochrane evidence based reviews: respiratory syncytial virus infections

Genetic Tests for Respiratory Syncytial Virus Infectious Disease

Anatomical Context for Respiratory Syncytial Virus Infectious Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

19
Upper Respiratory Tract, Lower Respiratory Tract

MalaCards organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

40
Bone Marrow, Bone, Neutrophil, Heart, Breast, Liver, Myeloid

Publications for Respiratory Syncytial Virus Infectious Disease

Articles related to Respiratory Syncytial Virus Infectious Disease:

(show top 50) (show all 439)
# Title Authors PMID Year
1
Antiviral drugs: current state of the art. 54 61
11418355 2001
2
Gene expression profiling of SARS-CoV-2 infections reveal distinct primary lung cell and systemic immune infection responses that identify pathways relevant in COVID-19 disease. 61
33333559 2021
3
The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. 61
33764693 2021
4
Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. 61
33200082 2021
5
Surveillance of common respiratory infections during the COVID-19 pandemic demonstrates the preventive efficacy of non-pharmaceutical interventions. 61
33582375 2021
6
The burden of respiratory syncytial virus infections among children with sickle cell disease. 61
33034160 2021
7
Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. 61
32449200 2020
8
Meteorological drivers of respiratory syncytial virus infections in Singapore. 61
33235232 2020
9
Influenza and respiratory syncytial virus infections in the oldest-old continent. 61
32594325 2020
10
Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. 61
32227102 2020
11
Severe influenza/respiratory syncytial virus infections and hospital antimicrobial stewardship opportunities: impact of a 4-year surveillance including molecular diagnosis. 61
32624029 2020
12
Epidemiological and clinical characteristics of children with acute respiratory viral infections in the Philippines: a prospective cohort study. 61
32950713 2020
13
Clinical impact and direct costs of nosocomial respiratory syncytial virus infections in the neonatal intensive care unit. 61
32305431 2020
14
Erratum: Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study. 61
32791536 2020
15
A three-dimensional A549 cell culture model to study respiratory syncytial virus infections. 61
32360024 2020
16
Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study. 61
32659789 2020
17
Advanced Live Attenuated Vaccines for the Prevention of Respiratory Syncytial Virus Infections in Young Children. 61
31549154 2020
18
Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. 61
31758310 2020
19
Ten years of severe respiratory syncytial virus infections in a tertiary paediatric intensive care unit. 61
31095832 2020
20
Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali. 61
30810160 2020
21
Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies. 61
32084214 2020
22
Respiratory syncytial virus infections in children 0-24 months of age in the community. 61
31521741 2020
23
Assessment and Validation of Syndromic Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis. 61
31568250 2019
24
Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines. 61
31607601 2019
25
Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. 61
31718741 2019
26
Respiratory Outcome of the Former Premature Infants. 61
32025257 2019
27
Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. 61
31517055 2019
28
Respiratory Tract Infections and Voice Quality in 4-Year-old Children in the STEPS Study. 61
29506899 2019
29
What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections? 61
31158780 2019
30
Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States. 61
31070757 2019
31
Acute Encephalitis and Myocarditis Associated with Respiratory Syncytial Virus Infections. 61
31380518 2019
32
Genomic analysis of respiratory syncytial virus infections in households and utility in inferring who infects the infant. 61
31296922 2019
33
Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children. 61
30814460 2019
34
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. 61
31221784 2019
35
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. 61
30202920 2019
36
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. 61
31143074 2019
37
Respiratory viruses in adults hospitalised with Community-Acquired Pneumonia during the non-winter months in Melbourne: Routine diagnostic practice may miss large numbers of influenza and respiratory syncytial virus infections. 61
30982246 2019
38
Notes from the Field: Respiratory Syncytial Virus Infections in a Neonatal Intensive Care Unit - Louisiana, December 2017. 61
30629570 2019
39
An overview of respiratory syncytial virus infections in Saudi Arabia. 61
32012121 2018
40
Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Asthmatic Children. 61
29742646 2018
41
Respiratory syncytial virus infections in India: Epidemiology and need for vaccine. 61
30880691 2018
42
Respiratory syncytial virüs infections in neonates and infants. 61
30116126 2018
43
Immunization during pregnancy. 61
29715051 2018
44
Case study-based time-course analysis of symptoms of respiratory syncytial virus infections followed by acute sinusitis in otherwise-healthy adults. 61
29997985 2018
45
Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections. 61
29463335 2018
46
Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. 61
29360277 2018
47
Dose-dependent relationships between weight status and clinical outcomes among infants hospitalized with respiratory syncytial virus infections. 61
29359458 2018
48
Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan. 61
29746578 2018
49
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. 61
29168012 2018
50
A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections. 61
29232863 2017

Variations for Respiratory Syncytial Virus Infectious Disease

Expression for Respiratory Syncytial Virus Infectious Disease

LifeMap Discovery
Genes differentially expressed in tissues of Respiratory Syncytial Virus Infectious Disease patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon alpha inducible protein 27 Blood + 6.10 0.000
2 OLFM4 olfactomedin 4 Blood + 5.54 0.000
3 PRTN3 proteinase 3 Blood + 5.47 0.000
4 CEACAM6 CEA cell adhesion molecule 6 Blood + 5.04 0.000
5 MMP8 matrix metallopeptidase 8 Blood + 4.32 0.000
6 MPO myeloperoxidase Blood + 4.23 0.000
7 HP haptoglobin Blood + 4.21 0.000
8 CTSG cathepsin G Blood + 4.10 0.000
9 DEFA4 defensin alpha 4 Blood + 3.98 0.000
10 OTOF otoferlin Blood + 3.94 0.000
11 OLFM1 olfactomedin 1 Blood - 3.93 0.000
12 RETN resistin Blood + 3.90 0.000
13 ARG1 arginase 1 Blood + 3.89 0.000
14 GPR84 G protein-coupled receptor 84 Blood + 3.88 0.000
15 CCN3 cellular communication network factor 3 Blood - 3.79 0.000
16 ELANE elastase, neutrophil expressed Blood + 3.76 0.000
17 RHAG Rh associated glycoprotein Blood + 3.73 0.000
18 CMPK2 cytidine/uridine monophosphate kinase 2 Blood + 3.68 0.000
19 MAOA monoamine oxidase A Blood + 3.62 0.000
20 ZDHHC19 zinc finger DHHC-type palmitoyltransferase 19 Blood + 3.62 0.000
21 CEACAM8 CEA cell adhesion molecule 8 Blood + 3.55 0.000
22 KCNG1 potassium voltage-gated channel modifier subfamily G member 1 Blood - 3.48 0.000
23 HBBP1 hemoglobin subunit beta pseudogene 1 Blood + 3.45 0.000
24 AZU1 azurocidin 1 Blood + 3.43 0.000
25 ANXA3 annexin A3 Blood + 3.42 0.000
26 COL17A1 collagen type XVII alpha 1 chain Blood + 3.39 0.000
27 CD177 CD177 molecule Blood + 3.38 0.000
28 PRSS33 serine protease 33 Blood - 3.36 0.000
29 METTL7B methyltransferase like 7B Blood + 3.33 0.000
30 GPR42 G protein-coupled receptor 42 Blood + 3.27 0.000
31 C1QC complement C1q C chain Blood + 3.24 0.000
32 KCTD14 potassium channel tetramerization domain containing 14 Blood + 3.22 0.000
33 DEFA3 defensin alpha 3 Blood + 3.20 0.000
34 FGF9 fibroblast growth factor 9 Blood - 3.15 0.000
35 PTGDR2 prostaglandin D2 receptor 2 Blood - 3.15 0.000
36 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.13 0.000
37 ADGRE4P adhesion G protein-coupled receptor E4, pseudogene Blood - 3.11 0.000
38 MMP28 matrix metallopeptidase 28 Blood - 3.09 0.000
39 XK X-linked Kx blood group Blood + 3.08 0.000
40 OAS3 2'-5'-oligoadenylate synthetase 3 Blood + 3.04 0.000
41 KIF5C kinesin family member 5C Blood - 3.03 0.000
42 DLK1 delta like non-canonical Notch ligand 1 Blood + 3.01 0.000
43 LRRC26 leucine rich repeat containing 26 Blood - 3.01 0.000
44 LTF lactotransferrin Blood + 3.00 0.000
Search GEO for disease gene expression data for Respiratory Syncytial Virus Infectious Disease.

Pathways for Respiratory Syncytial Virus Infectious Disease

Pathways related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 NEU1 IRF1 IL5 IL13 IFNB1 CCL5
2
Show member pathways
13.15 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
3
Show member pathways
12.74 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
4
Show member pathways
12.15 IL5 IL13 IFNB1
5
Show member pathways
11.91 IRF1 IL5 IL13 IFNB1
6 11.7 IRF1 IFNB1 CCL5
7 11.66 IRF1 IFNB1 CCL3
8 11.46 IRF1 IL5 IL13
9 11.4 IL5 IL13 CCL3
10 11.25 IL5 IL13
11 11.15 IRF1 IFNB1
12 11.12 IL13 CCL5 CCL3
13 11.07 IL5 IL13
14 11 IRF1 IL13
15 10.96 IL5 IL13
16 10.92 IFNB1 CCL5
17 10.73 IL5 IL13 CCL5 CCL3
18 10.72 IL5 IL13 CCL5 CCL3
19 10.59 IL5 IL13 IFNB1
20 10.57 IL5 IL13

GO Terms for Respiratory Syncytial Virus Infectious Disease

Cellular components related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 SFTPB IL5 IL13 IFNB1 CCL5 CCL3
2 extracellular region GO:0005576 9.17 SFTPB NEU1 IL5 IL13 IFNB1 CCL5

Biological processes related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.73 IL5 CCL5 CCL3
2 immune response GO:0006955 9.67 IL5 IL13 CCL5 CCL3
3 positive chemotaxis GO:0050918 9.59 CCL5 CCL3
4 monocyte chemotaxis GO:0002548 9.58 CCL5 CCL3
5 negative regulation of viral genome replication GO:0045071 9.58 IFNB1 CCL5
6 positive regulation of B cell proliferation GO:0030890 9.57 IL5 IL13
7 protein kinase B signaling GO:0043491 9.55 CCL5 CCL3
8 lymphocyte chemotaxis GO:0048247 9.54 CCL5 CCL3
9 positive regulation of JAK-STAT cascade GO:0046427 9.52 IL5 CCL5
10 lipopolysaccharide-mediated signaling pathway GO:0031663 9.51 CCL5 CCL3
11 positive regulation of innate immune response GO:0045089 9.49 IFNB1 CCL5
12 positive regulation of calcium ion transport GO:0051928 9.48 CCL5 CCL3
13 cellular response to interferon-beta GO:0035458 9.46 IRF1 IFNB1
14 inflammatory response GO:0006954 9.46 IL5 IL13 CCL5 CCL3
15 positive regulation of immunoglobulin production GO:0002639 9.43 IL5 IL13
16 eosinophil chemotaxis GO:0048245 9.4 CCL5 CCL3
17 macrophage chemotaxis GO:0048246 9.32 CCL5 CCL3
18 negative regulation by host of viral transcription GO:0043922 9.26 CCL5 CCL3
19 cytokine-mediated signaling pathway GO:0019221 9.02 IL5 IL13 IFNB1 CCL5 CCL3
20 positive regulation of natural killer cell chemotaxis GO:2000503 8.96 CCL5 CCL3

Molecular functions related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL5 CCL3
2 chemoattractant activity GO:0042056 9.4 CCL5 CCL3
3 CCR chemokine receptor binding GO:0048020 9.37 CCL5 CCL3
4 cytokine receptor binding GO:0005126 9.32 IL13 IFNB1
5 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 CCL3
6 phospholipase activator activity GO:0016004 9.16 CCL5 CCL3
7 cytokine activity GO:0005125 9.02 IL5 IL13 IFNB1 CCL5 CCL3
8 CCR1 chemokine receptor binding GO:0031726 8.96 CCL5 CCL3

Sources for Respiratory Syncytial Virus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....